The pharmacology of mTOR inhibition

Science Signaling

Volumn 2, Issue 67, 2009, Pages

  Guertin, David A ^a   Sabatini, David M ^a,b  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; CURCUMIN; CYCLIN DEPENDENT KINASE INHIBITOR; DEFOROLIMUS; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MVP BEZ 235; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PP 242; PP 30; PROTEIN KINASE B INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TEMSIROLIMUS; TORIN 1; UNCLASSIFIED DRUG; XL 765; CRTC2 PROTEIN, HUMAN; DRUG DERIVATIVE; FK 506 BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MTORC1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RIDAFOROLIMUS; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENDOMETRIUM CANCER; ENZYME ACTIVE SITE; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; GENE OVEREXPRESSION; HUMAN; KIDNEY CARCINOMA; NEOPLASM; NONHUMAN; OUTPATIENT DEPARTMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; ARTICLE; BIOLOGICAL MODEL; DRUG EFFECT; METABOLISM; PROTEIN BINDING;

MAMMALIA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS; TACROLIMUS BINDING PROTEIN 1A; TRANSCRIPTION FACTORS;

EID: 68149096799     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.267pe24     Document Type: Review

References (37)

1. D. A. Guertin, D. M. Sabatini, Defining the role of mTOR in cancer. Cancer Cell 12, 9-22 (2007).
2. Q. Yang, K. L. Guan, Expanding mTOR signaling. Cell Res. 17, 666-681 (2007). (Pubitemid 47255937)
3. T. R. Peterson, M. Laplante, C. C. Thoreen, Y. Sancak, S. A. Kang, W. M. Kuel, N. S. Gray, D. M. Sabatini, DEPTOR is an mTOR inhibitor that is overexpressed in multiple myeloma cells and necessary for their survival. Cell, in press.
4. J. Huang, B. D. Manning, A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem. Soc. Trans. 37, 217-222 (2009).
5. E. M. Smith, S. G. Finn, A. R. Tee, G. J. Browne, C. G. Proud, The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J. Biol. Chem. 280, 18717-18727 (2005).
6. Y. Sancak, T. R. Peterson, Y. D. Shaul, R. A. Lindquist, C. C. Thoreen, L. Bar-Peled, D. M. Sabatini, The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320, 1496-1501 (2008); published online 21 May 2008 (10.1126/science.1157535). (Pubitemid 351929429)
7. E. Kim, P. Goraksha-Hicks, L. Li, T. P. Neufeld, K. L. Guan, Regulation of TORC1 by Rag GTPases in nutrient response. Nat. Cell Biol. 10, 935-945 (2008).
8. T. L. Yuan, L. C. Cantley, PI3K pathway alterations in cancer: Variations on a theme. Oncogene 27, 5497-5510 (2008).
9. V. P. Krymskaya, E. A. Goncharova, PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects. Cell Cycle 8, 403-413 (2009).
10. H. A. Lane, M. Breuleux, Optimal targeting of the mTORC1 kinase in human cancer. Curr. Opin. Cell. Biol., published online 21 February 2009 (10.1016/j.ceb.2009.01.016).
11. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, A. Kapoor, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovacevic, V. Lesovoy, I. G. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, R. J. Motzer, Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007). (Pubitemid 46849157)
12. A. Y. Choo, S. O. Yoon, S. G. Kim, P. P. Roux, J. Blenis, Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. U.S.A. 105, 17414-17419 (2008).
13. C. C. Thoreen, S. A. Kang, J. W. Chang, Q. Liu, J. Zhang, Y. Gao, L. J. Reichling, T. Sim, D. M. Sabatini, N. S. Gray, An ATP-competitive mTOR inhibitor reveals rapamycin-insensitive functions of mTORC1. J. Biol. Chem. 284, 8023-8032 (2009).
14. M. E. Feldman, B. Apsel, A. Uotila, R. Loewith, Z. A. Knight, D. Ruggero, K. M. Shokat, Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 7, e38 (2009).
15. N. V. Dorrello, A. Peschiaroli, D. Guardavaccaro, N. H. Colburn, N. E. Sherman, M. Pagano, S6K1- and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 314, 467-471 (2006). (Pubitemid 44628968)
16. M. K. Holz, B. A. Ballif, S. P. Gygi, J. Blenis, mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123, 569-580 (2005). (Pubitemid 41608461)
17. E. Jacinto, V. Facchinetti, D. Liu, N. Soto, S. Wei, S. Y. Jung, Q. Huang, J. Qin, B. Su, SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127, 125-137 (2006). (Pubitemid 44466632)
18. C. Shiota, J. T. Woo, J. Lindner, K. D. Shelton, M. A. Magnuson, Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11, 583-589 (2006). (Pubitemid 44430900)
19. D. A. Guertin, D. M. Stevens, C. C. Thoreen, A. A. Burds, N. Y. Kalaany, J. Moffat, M. Brown, K. J. Fitzgerald, D. M. Sabatini, Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCa, but not S6K1. Dev. Cell 11, 859-871 (2006). (Pubitemid 44804279)
20. J. M. Garcia-Martinez, D. R. Alessi, mTOR complex-2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid- induced protein kinase 1 (SGK1). Biochem. J. 416, 375-385 (2008).
21. D. D. Sarbassov, D. A. Guertin, S. M. Ali, D. M. Sabatini, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
22. T. A. Yap, M. D. Garrett, M. I. Walton, F. Raynaud, J. S. de Bono, P. Workman, Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8, 393-412 (2008).
23. S. M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, D. Fabbro, D. Gabriel, M. Simonen, L. Murphy, P. Finan, W. Sellers, C. Garcia-Echeverria, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
24. V. Serra, B. Markman, M. Scaltriti, P. J. Eichhorn, V. Valero, M. Guzman, M. L. Botero, E. Llonch, F. Atzori, S. Di Cosimo, M. Maira, C. Garcia-Echeverria, J. L. Parra, J. Arribas, J. Baselga, NVPBEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 68, 8022-8030 (2008).
25. C. R. Schnell, F. Stauffer, P. R. Allegrini, T. O'Reilly, P. M. McSheehy, C. Dartois, M. Stumm, R. Cozens, A. Littlewood-Evans, C. Garcia-Echeverria, S. M. Maira, Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: Implications for clinical imaging. Cancer Res. 68, 6598-6607 (2008).
26. J. A. Engelman, L. Chen, X. Tan, K. Crosby, A. R. Guimaraes, R. Upadhyay, M. Maira, K. McNamara, S. A. Perera, Y. Song, L. R. Chirieac, R. Kaur, A. Lightbown, J. Simendinger, T. Li, R. F. Padera, C. Garcia-Echeverria, R. Weissleder, U. Mahmood, L. C. Cantley, K. K. Wong, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008).
27. D. D. Sarbassov, S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard, D. M. Sabatini, Prolonged rapamycin treatment in-hibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168 (2006).
28. J. Copp, G. Manning, T. Hunter, TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): Phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69, 1821-1827 (2009).
29. B. Shor, W. G. Zhang, L. Toral-Barza, J. Lucas, R. T. Abraham, J. J. Gibbons, K. Yu, A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res. 68, 2934-2943 (2008). (Pubitemid 351556294)
30. A. Barquilla, J. L. Crespo, M. Navarro, Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation. Proc. Natl. Acad. Sci. U.S.A. 105, 14579-14584 (2008).
31. C. Nardella, A. Carracedo, A. Alimonti, R. M. Hobbs, J. G. Clohessy, Z. Chen, A. Egia, A. Fornari, M. Fiorentino, M. Loda, S. C. Kozma, G. Thomas, C. Cordon-Cardo, P. P. Pandolfi, Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci. Signal. 2, ra2 (2009).
32. D. A. Guertin, D. M. Stevens, M. Saitoh, S. Kinkel, K. Crosby, J. H. Sheen, D. J. Mullholland, M. A. Magnuson, H. Wu, D. M. Sabatini, mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15, 148-159 (2009).
33. C. F. Bentzinger, K. Romanino, D. Cloetta, S. Lin, J. B. Mascarenhas, F. Oliveri, J. Xia, E. Casanova, C. F. Costa, M. Brink, F. Zorzato, M. N. Hall, M. A. Ruegg, Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab. 8, 411-424 (2008).
34. A. Kumar, T. E. Harris, S. R. Keller, K. M. Choi, M. A. Magnuson, J. C. Lawrence Jr., Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances basal glycogen synthase activity. Mol. Cell. Biol. 28, 61-70 (2008).
35. C. S. Beevers, L. Chen, L. Liu, Y. Luo, N. J. Webster, S. Huang, Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res. 69, 1000-1008 (2009).
36. Z. A. Knight, B. Gonzalez, M. E. Feldman, E. R. Zunder, D. D. Goldenberg, O. Williams, R. Loewith, D. Stokoe, A. Balla, B. Toth, T. Balla, W. A. Weiss, R. L. Williams, K. M. Shokat, A pharmacological map of the PI3-K family defines a role for p110a in insulin signaling. Cell 125, 733-747 (2006).
37. We thank T. DiCesare for graphics support and S. Kinkel for critical reading of the manuscript. D.A.G. is supported by a grant from the NIH (K99CA-1296613). D.M.S. is supported by grants from the NIH (R01-AI47389 and R01-CA103866) and awards from the Keck Foundation and the LAM (Lymphangioleiomyomatosis) Foundation and is an investigator of the Howard Hughes Medical Institute.